Home > Compound List > Compound details
96036-03-2 molecular structure
click picture or here to close

(4R,5S,6S)-3-{[(2S,5S)-5-(dimethylcarbamoyl)pyrrolidin-2-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

ChemBase ID: 640
Molecular Formular: C17H25N3O5S
Molecular Mass: 383.4625
Monoisotopic Mass: 383.15149192
SMILES and InChIs

SMILES:
S(C1=C(N2[C@@H]([C@H](C2=O)[C@H](O)C)[C@H]1C)C(=O)O)[C@@H]1N[C@@H](CC1)C(=O)N(C)C
Canonical SMILES:
C[C@H]([C@H]1C(=O)N2[C@@H]1[C@@H](C)C(=C2C(=O)O)S[C@H]1CC[C@H](N1)C(=O)N(C)C)O
InChI:
InChI=1S/C17H25N3O5S/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-10-6-5-9(18-10)15(22)19(3)4/h7-12,18,21H,5-6H2,1-4H3,(H,24,25)/t7-,8-,9+,10+,11-,12-/m1/s1
InChIKey:
FSTGLKRHSQANLP-PQTSNVLCSA-N

Cite this record

CBID:640 http://www.chembase.cn/molecule-640.html

Collapse All Expand All

NAMES AND DATABASE IDS

NAMES AND DATABASE IDS

Names Database IDs
IUPAC name
(4R,5S,6S)-3-{[(2S,5S)-5-(dimethylcarbamoyl)pyrrolidin-2-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
IUPAC Traditional name
merrem I.V.
meropenem
Brand Name
Merrem I.V.
Merrem
Meronem
Synonyms
Meropenemum [INN-Latin]
Meropenem anhydrous
Antibiotic SM 7338
meropenem
Meropenem
CAS Number
96036-03-2
119478-56-7
MDL Number
MFCD00864966
PubChem SID
160964103
PubChem CID
64778

DATA SOURCES

DATA SOURCES

All Sources Commercial Sources Non-commercial Sources
Data Source Data ID Price
Bide Pharmatech
BD23263 Please log in.

CALCULATED PROPERTIES

CALCULATED PROPERTIES

JChem ALOGPS 2.1
Acid pKa 3.4608822  H Acceptors
H Donor LogD (pH = 5.5) -3.8944511 
LogD (pH = 7.4) -4.1434183  Log P -3.898237 
Molar Refractivity 97.7742 cm3 Polarizability 37.882397 Å3
Polar Surface Area 110.18 Å2 Rotatable Bonds
Lipinski's Rule of Five true 
Log P -0.8  LOG S -1.83 
Solubility (Water) 5.64e+00 g/l 

PROPERTIES

PROPERTIES

Physical Property Product Information Bioassay(PubChem)
Solubility
Sparingly expand Show data source
Hydrophobicity(logP)
-0.6 expand Show data source
Purity
95+% expand Show data source

DETAILS

DETAILS

DrugBank DrugBank
DrugBank - DB00760 external link
Item Information
Drug Groups approved; investigational
Description Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.
Indication For use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (excluding vancomycin-resistant isolates), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis and Peptostreptococcus species; complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. Also for use in the treatment of bacterial meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (b-lactamase and non-b-lactamase-producing isolates), and Neisseria meningitidis.
Pharmacology Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.
Toxicity In mice and rats, large intravenous doses of meropenem (2200-4000 mg/kg) have been associated with ataxia, dyspnea, convulsions, and mortalities.
Affected Organisms
Enteric bacteria and other eubacteria
Biotransformation Primarily excreted unchanged. There is one metabolite which is microbiologically inactive.
Half Life Approximately 1 hour in adults and children 2 years of age and older with normal renal function. Approximately 1.5 hours in children 3 months to 2 years of age.
Protein Binding Approximately 2%.
Elimination Approximately 70% of the intravenously administered dose is recovered as unchanged meropenem in the urine over 12 hours, after which little further urinary excretion is detectable.
External Links
Wikipedia
RxList
Drugs.com

REFERENCES

REFERENCES

From Suppliers Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
    No data available
  • Searching...Please wait...

PATENTS

PATENTS

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

INTERNET

INTERNET

Baidu iconBaidu google iconGoogle